Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

The adipose-neural axis is involved in epicardial adipose tissue-related cardiac arrhythmias

Fan Y., Huang S., Li S., Wu B., Zhao Q., Huang L.

Prospective Study on Cardiovascular Disease, published in Cell Rep Med (2024) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Cell Rep Med (2024)
Reported sample size
—
Source database
Europe PMC
PMID
38744275
PMCID
PMC11148799
DOI
10.1016/j.xcrm.2024.101559
Citations
13

Abstract (original English)

Dysfunction of the sympathetic nervous system and increased epicardial adipose tissue (EAT) have been independently associated with the occurrence of cardiac arrhythmia. However, their exact roles in triggering arrhythmia remain elusive. Here, using an in vitro coculture system with sympathetic neurons, cardiomyocytes, and adipocytes, we show that adipocyte-derived leptin activates sympathetic neurons and increases the release of neuropeptide Y (NPY), which in turn triggers arrhythmia in cardiomyocytes by interacting with the Y1 receptor (Y1R) and subsequently enhancing the activity of the Na + /Ca 2+ exchanger (NCX) and calcium/calmodulin-dependent protein kinase II (CaMKII). The arrhythmic phenotype can be partially blocked by a leptin neutralizing antibody or an inhibitor of Y1R, NCX, or CaMKII. Moreover, increased EAT thickness and leptin/NPY blood levels are detected in atrial fibrillation patients compared with the control group. Our study provides robust evidence that the adipose-neural axis contributes to arrhythmogenesis and represents a potential target for treating arrhythmia.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
PericardiumNeuronsSympathetic Nervous SystemAdipose TissueAdipocytesMyocytes, CardiacAnimalsHumansMiceAtrial Fibrillation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research